Who
Christopher Ryan Sullivan
Chief Financial Officer
Company insider
Files Form 4 as: Chief Financial Officer, Avalo Therapeutics.
In numbers
- Trades disclosed
- 91
- Buys
- 4
- Sells
- 10
- Bought
- $22K
- Sold
- $7.4M
- Companies
- 1
- Companies where not an officer
- 0
- First trade
- 10 Jun 2020
- Last trade
- 16 Sep 2026
- Last filed
- 18 Sep 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 16 Sep 2026filed 18 Sep 2026 | AVTX Avalo TherapeuticsBiotechnology | SEC FORM 4 Code M | $122K12,394 at $9.88 | filing |
| 16 Sep 2026filed 18 Sep 2026 | AVTX Avalo TherapeuticsBiotechnology | SEC FORM 4 Sold | $202K12,394 at $16.33 | filing |
| 16 Sep 2026filed 18 Sep 2026 | AVTX Avalo Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —12,394 at $0.00 | filing |
| 16 Sep 2026filed 18 Sep 2026 | AVTX Avalo Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —12,394 at $0.00 | filing |
| 16 Sep 2026filed 18 Sep 2026 | AVTX Avalo TherapeuticsBiotechnology | SEC FORM 4 Code M | $122K12,394 at $9.88 | filing |
| 16 Sep 2026filed 18 Sep 2026 | AVTX Avalo TherapeuticsBiotechnology | SEC FORM 4 Sold | $202K12,394 at $16.33 | filing |
| 10 Sep 2026filed 11 Sep 2026 | AVTX Avalo TherapeuticsBiotechnology | SEC FORM 4 Code M | $82K10,185 at $8.04 | filing |
| 10 Sep 2026filed 11 Sep 2026 | AVTX Avalo TherapeuticsBiotechnology | SEC FORM 4 Sold | $179K10,185 at $17.62 | filing |
| 10 Sep 2026filed 11 Sep 2026 | AVTX Avalo Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —10,185 at $0.00 | filing |
| 10 Sep 2026filed 11 Sep 2026 | AVTX Avalo Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —10,185 at $0.00 | filing |
| 10 Sep 2026filed 11 Sep 2026 | AVTX Avalo TherapeuticsBiotechnology | SEC FORM 4 Code M | $82K10,185 at $8.04 | filing |
| 10 Sep 2026filed 11 Sep 2026 | AVTX Avalo TherapeuticsBiotechnology | SEC FORM 4 Sold | $179K10,185 at $17.62 | filing |
| 18 Aug 2026filed 19 Aug 2026 | AVTX Avalo Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —31,031 at $0.00 | filing |
| 18 Aug 2026filed 19 Aug 2026 | AVTX Avalo TherapeuticsBiotechnology | SEC FORM 4 Code M | $307K31,031 at $9.88 | filing |
| 18 Aug 2026filed 19 Aug 2026 | AVTX Avalo TherapeuticsBiotechnology | SEC FORM 4 Sold | $622K31,031 at $20.05 | filing |
| 18 Aug 2026filed 19 Aug 2026 | AVTX Avalo Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —31,031 at $0.00 | filing |
| 18 Aug 2026filed 19 Aug 2026 | AVTX Avalo TherapeuticsBiotechnology | SEC FORM 4 Code M | $307K31,031 at $9.88 | filing |
| 18 Aug 2026filed 19 Aug 2026 | AVTX Avalo TherapeuticsBiotechnology | SEC FORM 4 Sold | $622K31,031 at $20.05 | filing |
| 17 Aug 2026filed 19 Aug 2026 | AVTX Avalo TherapeuticsBiotechnology | SEC FORM 4 Code M | $375K37,945 at $9.88 | filing |
| 17 Aug 2026filed 19 Aug 2026 | AVTX Avalo TherapeuticsBiotechnology | SEC FORM 4 Code M | $28K2,876 at $9.88 | filing |
News
Christopher Ryan Sullivan Sells 10,185 Shares of Avalo Therapeutics (NASDAQ:AVTX) Stockthemarketsdaily.com · 13 Sep 2026Head-To-Head Survey: Avalo Therapeutics (NASDAQ:AVTX) & Ascendis Pharma A/S (NASDAQ:ASND)AVTX · themarketsdaily.com · 22 Oct 2026Avalo Therapeutics (NASDAQ:AVTX) versus Praxis Precision Medicines (NASDAQ:PRAX) Financial AnalysisAVTX · tickerreport.com · 16 Oct 2026Avalo Therapeutics (NASDAQ:AVTX) Stock Falls 6.6% – Should You Sell?AVTX · dailypolitical.com · 13 Oct 2026
1 headline in the last 90 days name Christopher Ryan Sullivan; 3 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.